Does higher serum phosphate within the reference range indicate increased cardiovascular risk?

Evidence from clinical and mechanistic studies supports the observation that serum phosphate levels, even when they remain within the standard laboratory reference range, are significant indicators of total phosphate burden and cardiovascular health.

Clinical effectiveness and cardiovascular risk

Higher serum phosphate levels are consistently linked to adverse cardiovascular outcomes, even in individuals with normal kidney function.

• Cardiovascular Mortality: Meta-analyses of over 128,000 adults show that individuals in the highest quartiles of the "normal" phosphate range have a 44% higher risk of cardiovascular mortality (HR 1.44) and coronary atherosclerosis (OR 1.44) compared to those in lower quartiles.
• Vascular Calcification: In populations with an eGFR > 60 mL/min/1.73m², phosphate levels between 3.2 and 4.0 mg/dL are significantly associated with higher odds of coronary artery calcification.
• Causal Evidence: Mendelian randomization studies suggest a causal link between genetically higher serum phosphate and the development of valvular heart disease.

Mechanistic explanations

The relationship between phosphate and cardiovascular damage is driven by specific endocrine and cellular pathways.

• FGF23/PTH Axis: Serum phosphate is a primary trigger for Fibroblast Growth Factor 23 (FGF23) secretion. As phosphate burden increases, FGF23 rises to promote renal excretion. High FGF23 then suppresses active vitamin D (1,25(OH)₂D), which reduces calcium absorption and leads to secondary increases in Parathyroid Hormone (PTH).
• Vascular Transformation: High-normal phosphate levels promote the "osteogenic differentiation" of vascular smooth muscle cells. This process, mediated by mitochondrial oxidative stress and sodium-dependent phosphate transporters, essentially causes blood vessels to begin taking on bone-like characteristics (calcification).
• Cardiac Impact: While FGF23 helps clear phosphate, its chronic elevation independently promotes left ventricular hypertrophy and cardiac oxidative stress, further escalating risk.

Role of kidney function

The clinical impact of phosphate burden is closely tied to the kidney's excretion capacity (eGFR).

• Risk Scaling: While the association between phosphate and mortality exists across all eGFR levels, the magnitude of risk is more pronounced as kidney function declines. In advanced CKD (stages 3–5), the mortality risk associated with high phosphate can be up to four times higher than in healthy populations.
• Homeostatic Breakdown: In early-stage kidney disease, serum phosphate may appear normal only because FGF23 and PTH levels have risen significantly to compensate. Thus, a "high-normal" phosphate level in a patient with lower eGFR often signifies that these compensatory mechanisms are nearing their limit.

Bottom line

Serum phosphate at the higher end of the reference range is a robust marker of increased cardiovascular risk. This risk is driven by pathological vascular calcification and the elevation of regulatory hormones like FGF23, and it becomes progressively more clinically significant as kidney excretion capacity declines.